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to total mesorectum and pelvic lymphatic drainage with 
simultaneous integrated boost (SIB) to the tumor bed and 
adjacent mesorectum. Fluoropirimidine-based CT was 
administered. The acute toxicity was evaluated according to 
CTCAE 4.0 scale. 
 
Results: Pts characteristics: median age 63.5yy (range 29-
84), median tumor distance-IAS 50 mm (range 0-100), median 
tumor size 50 mm (range 25-120), MRF involvement 24 pts, 
Stage IIA 7 pts – III 62 pts. All of the pts completed the RT; 45 
Gy were delivered to total mesorectum and lymphatic 
drainage with median SIB dose of 55 Gy (range 52.5-57.5). 
Forty-nine (71%) pts received concomitant CT with 
capecitabine alone and 17 (25%) capecitabine plus 
oxaliplatin. Globally, 16/69 (23%) pts did not complete CT for 
haematological (5) or, gastrointestinal toxicities (5) and 
other causes (6). Fourteen (20%), 33 (48%) and 23 (33%) pts 
experienced grade 1-2 haematological, gastrointestinal and 
genitourinary toxicity, respectively. Two out of 69 (3%) pts 
developed grade 3 haematological toxicity and 9/69 (13%) 
grade 3 gastrointestinal toxicity. Forty-three pts underwent 
surgery (LAR 28, APR 10, local excision 5 pts) but definitive 
histology is not yet available in 7 pts. Twenty-six pts are 
waiting for surgery. The tumor downstaging was documented 
in 29/36 (80.5%) pts. Forty-four rate (16/36) of surgical cases 
achieved pathologic complete response. 
 
Conclusion: Despite the limitations related to the 
heterogeneity of the treatment delivery (SIB dose and 
concomitant CT), the RT dose-escalation in the preoperative 
treatment of LARC seems feasible, well tolerated and 
effective in terms of tumor downstaging and pathological 
complete response. Nevertheless, this results need to be 
confirmed on a larger cohort. 
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Purpose or Objective: To report the results of a 
retrospective pooled analysis of anal carcinoma (AC) patients 
treated with IMRT, VMAT, helical tomotherapy (HT) and daily 
image-guided RT (IGRT) in 3 Swiss radiotherapy centers. 
 
Material and Methods: Local control (LC) and grade 3 or 
more toxicity rate (CTCAE v.4.0) were the primary endpoints. 
Overall (OS), disease-free (DFS), distant metastasis-free 
(DMFS) and colostomy-free survival (CFS) were also studied. 
Volumes were defined as follows: CTV1 : Anal canal, 
mesorectal, pelvic, and inguinal nodes. CTV2 : anal tumor 
and clinically positive nodes. Planning target volumes were 
obtained by adding 5-mm margin to the CTV (PTV1 and PTV2, 
respectively). PTV1 received 36 Gy (1.8 Gy/fraction) 
delivered with IMRT (n = 44), VMAT (n = 16) or HT (n = 100), 
while PTV2 received a sequential boost up to a total dose of 
59.4-60 Gy (1.8-2 Gy/fr), delivered with IMRT (n = 16), VMAT 
(n = 18) , HT (n = 59) or 3D-conformal RT (CRT, n = 67). 
 
Results: From 03.2006 to 04.2015, 160 patients were treated; 
30, 68, 60 and 2 patients presented stage I, II, III, and IV, 
respectively. Median age was 62 years (range: 35-89). A 
planned gap was used in 130 patients. Median gap duration 
was 10 days (range, 5-24). Concomitant chemotherapy (CTX) 
was delivered in 149 patients, mainly using mitomycine C 
combined with fluoropyrimidines (i.v. or oral, n = 139). 
Median follow-up was 45 months (range: 3-97). Four-year LC, 
OS, DFS, DMFS and CFS rates were 83.6%, 82.3%, 82.7%, 93.4% 
and 88%, respectively. Time to progression for relapsing 
patients was 29 months (range: 1-78). A total of 24 patients 
presented a recurrence (local only in 14, locoregional in 1, 
locoregional and distant in 1, local and distant in 3, regional 
only in 2, and distant only in 3 patients). Fourteen patients 
underwent a colostomy because of local recurrence (n = 12) 
or pretreatment anal sphincter dysfunction (n = 2). Grade 3 
acute toxicity was observed in 30 patients (18.4%), usually as 
erythema (23/30) or diarrhoea (10/30). No late G3 cutaneous 
toxicity was recorded. At the time of analysis, 150 patients 
presented more than 6 months of follow-up and were 
considered evaluable for late toxicity. Data about late 
toxicity were not available for 6 patients, followed in other 
Institutions. Looking at the final 144 patients, 3 of them 
patients presented a late G3 gastrointestinal toxicity (anal 
incontinence). No G4 acute or late toxicity was recorded. No 
significant differences were observed in terms of local 
control or acute G3 toxicity between IMRT and 3D-CRT boost 
techniques.  
 
Conclusion: A total dose of 59.4/60 Gy to the anal tumor and 
involved nodes, including 36 Gy to the elective nodal regions 
, is effective and safe when delivered using modern IMRT 
techniques and daily IGRT. Thus, VMAT or HT and concurrent 
CTX are the standard of care in our institutions. 
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Purpose or Objective: The aim of the study was to analyze if 
time from neo-adjuvant chemoradiotherapy (CTRT) to radical 
surgery influences oncologic outcomes in locally advanced 
rectal cancer.  
 
Material and Methods: We performed a retrospective 
analysis of 132 consecutive patients with rectal cancer 
treated at our Institute from March 2006 to March 2013 who 
underwent to neoadjuvant therapy followed by radical 
resection. Of these, 12 patients were excluded as lost at 
follow up, 3 patients for peritoneal carcinosis detection at 
surgery time and 3 patients refused surgery after 
neoadjuvant treatment. The remaining patients were 
analyzed and divided into two groups according to time to 
surgery (group A ≤ 8 weeks and group B > 8 weeks) after 
completion of CTR 
 
Results: A total of 114 patients underwent total mesorectal 
excision (TME) after neoadjuvant treatment for stage II and 
III rectal cancer between 0 and 15 cm from anal verge. There 
were 51 (45%) patients in group A (interval ≤ 8 weeks) and 63 
(55%) in group B (interval > 8 weeks). Median time from 
chemo-radiotherapy and surgery was 7 weeks (range 1-8) and 
12 weeks ( range 9-17), respectively, in group A and B. In 
group B there was a major number of patients with no 
involvement of circumferential resection margin (CRM), 60 vs 
48, and a higher number of major pathologic responce (pT0 – 
pT1), 19 vs 9. Disease free survival (DFS) at 5 years was 85.7% 
vs 75.9% and overall survival (OS) at 5 years was 83.7% vs 92% 
in group A vs group B. 
 
Conclusion: In our analysis we did not reach statistical 
significance difference as regards DFS and OS in the two 
groups of patients; however we observed a favorable trend in 
the group of patients that underwent to surgery after 8 
weeks from neoadjuvant treatment in terms of pathological 
responce and free radial margin. 
 
 
